Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with primary liver cancer (hepatocellular carcinoma, or HCC), either through clinical assessment or confirmed by tissue testing
- People whose liver tumor measures more than 10 cm across on medical imaging taken before joining the trial
- People aged between 18 and 75 years
- People whose cancer has not spread into major blood vessels near the liver or to other parts of the body
- People who have had surgery to fully remove the liver tumor, with enough healthy liver tissue remaining afterward
- People whose liver function falls within an acceptable range, as measured by a score called the ALBI grade (grades I or II)
- People who are generally well enough to carry out daily activities, as measured by a standard health performance scale (ECOG score of 0 or 1)
- People whose blood test results fall within acceptable ranges for red blood cells, bilirubin, liver enzymes, and kidney function (confirm specific values with trial site)
- People whose blood clotting results are within an acceptable range, as measured by specific blood tests (confirm with trial site)
Who may not be able to join:
- People whose liver cancer has spread into major blood vessels or to other parts of the body
- People whose tumor measured 10 cm or less across on imaging before joining
- People whose liver cancer has come back after a previous occurrence (recurrent HCC)
- People who have other serious medical conditions alongside their liver cancer
- People who have high blood pressure in the liver's blood vessels (portal hypertension), including those with swollen veins in the food pipe or an enlarged spleen combined with a low platelet count
- People who have irregular heart rhythms that require medication to control
- People whose medical records are incomplete or who may not be able to attend follow-up appointments within the first three months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Feng Duan, MD, Chinese PLA General Hospital
Phone: 19868000115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Recurrence-free survival （RFS）
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.